These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 31127325

  • 21. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
    Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H.
    Tohoku J Exp Med; 2016 Dec; 240(4):259-268. PubMed ID: 27904005
    [Abstract] [Full Text] [Related]

  • 22. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
    Caro Martinez C, Cerezo Manchado JJ, Flores Blanco PJ, Elvira Ruíz G, Albendín Iglesias H, Lova Navarro A, Arregui Montoya F, García Alberola A, Andrés Pascual Figal D, Bailén Lorenzo JL, Navarro-Almenzar B, García-Candel F, Manzano Fernández S.
    Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
    [Abstract] [Full Text] [Related]

  • 23. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
    Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, XANTUS Investigators.
    Eur Heart J; 2016 Apr 07; 37(14):1145-53. PubMed ID: 26330425
    [Abstract] [Full Text] [Related]

  • 24. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW, Svanström H, Lund M, Pasternak B, Melbye M.
    Int J Cardiol; 2018 Oct 01; 268():113-119. PubMed ID: 29934230
    [Abstract] [Full Text] [Related]

  • 25. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
    Yagi N, Suzuki S, Arita T, Otsuka T, Semba H, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Yajima J, Matsuhama M, Yamashita T.
    Heart Vessels; 2020 Jan 01; 35(1):110-117. PubMed ID: 31222552
    [Abstract] [Full Text] [Related]

  • 26. Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: A report from a prospective European observational registry.
    Mei DA, Imberti JF, Bonini N, Romiti GF, Corica B, Proietti M, Vitolo M, Lip GYH, Boriani G.
    Eur J Intern Med; 2024 Oct 01; 128():63-70. PubMed ID: 38969571
    [Abstract] [Full Text] [Related]

  • 27. Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study.
    Atarashi H, Uchiyama S, Inoue H, Kitazono T, Yamashita T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Shimokawa H.
    Heart Vessels; 2021 Sep 01; 36(9):1410-1420. PubMed ID: 33728513
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness and Safety of Rivaroxaban by General Practitioners　- A Multicenter, Prospective Study in Japanese Patients With Non-Valvular Atrial Fibrillation (GENERAL).
    Kusano K, Sugishita N, Akao M, Tsuji H, Matsui K, Hiramitsu S, Hatori Y, Odakura H, Kamada H, Miyamoto K, Ogawa H.
    Circ J; 2021 Jul 21; 85(8):1275-1282. PubMed ID: 33814525
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
    Gedikli Ö, Altay S, Ünlü S, Çakmak HA, Aşkın L, Yanık A, Beşli F, Sinan ÜY, Canpolat U, Şahin M, Pehlivanoğlu S.
    Anatol J Cardiol; 2021 Mar 21; 25(3):196-204. PubMed ID: 33690135
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG.
    Arch Cardiovasc Dis; 2019 Mar 21; 112(6-7):400-409. PubMed ID: 31014991
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
    Akao M, Yasuda S, Kaikita K, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H.
    Am Heart J; 2021 Jun 21; 236():59-68. PubMed ID: 33657403
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.
    Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):70-79. PubMed ID: 30423165
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.